Antibody Design and Production Services
In recent years, the proportion of biological drugs in the global pharmaceutical market has been close to 20%. The focus within the global pharmaceutical market has been gradually shifting from small molecule chemical drugs to biomacromolecules (biological drugs). It also appears that the trend is gradually expanding. Biological drugs are a broad class of pharmaceuticals generated by using principles and methods of biology, immunology, physical chemistry, and pharmacology, etc. These drugs utilize the composition of various organisms and biological tissues, as well as organs. Biological drugs usually include genetic engineering drugs, antibody engineering drugs, blood products drugs, and vaccines etc. Among these, antibody drugs are one of the fastest growing human therapeutic drugs.
This increase in research and development has proved to be an effective treatment for many important diseases such as cancer, chronic inflammatory diseases, cardiovascular diseases, immune system diseases, and infectious diseases. The antibody research and development also plays an important role in medicine and diagnostics.
Synbio Technologies’ Antibody Platform utilizes molecular simulation technologies to provide antibody de novo design and preparation services. We use this platform to simulate various biological behaviors of antibody molecules on the atomic level. We can analyze the antibody structure as a starting point to solve a series of problems such as the theoretical design of an antibody. The combination of the molecular simulation technology and experimental approach can help our customers effectively reduce the total cost of antibody R&D to effectively shorten the R&D cycle.
- Powerful drug-like antibody bio-computation
- Cloud computing
- Facilitate the development of “biologically superior” antibody drugs
- Antibodies humanization
- Affinity maturation
- Full human antibody library design
- Proprietary software platforms
- High-throughput antibody modeling
- Effective antigen-antibody docking
- Therapeutic antibodies have been licensed